ABBV 553

Drug Profile

ABBV 553

Alternative Names: ABBV-553

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inventiva Pharma
  • Developer AbbVie; Inventiva Pharma
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psoriasis

Most Recent Events

  • 02 Nov 2017 AbbVie terminates a phase I trial in Psoriasis (In adults, In the elderly) in USA due to safety reason (PO) (NCT03145948)
  • 25 Sep 2017 Development discontinued for psoriasis during 2017
  • 28 Aug 2017 AbbVie withdraws phase I trial in psoriasis in USA, prior to enrolment, due to safety reason (NCT03145948)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top